Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Gray platelet syndrome

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44294   clinical trials with a EudraCT protocol, of which   7351   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    5 result(s) found for: Gray platelet syndrome. Displaying page 1 of 1.
    EudraCT Number: 2019-002833-12 Sponsor Protocol Number: GRAY-ZONE Start Date*: 2020-01-27
    Sponsor Name:University Medical Centre Hamburg-Eppendorf
    Full Title: Investigator-initiated, placebo-controlled, randomized trial to assess the efficacy and safety of platelet inhibition and/ or lipid lowering in non-ACS-patients with elevated high-sensitivity tropo...
    Medical condition: Myocardial Ischemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10028601 Myocardial ischemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-007258-75 Sponsor Protocol Number: 20060198 Start Date*: 2008-08-22
    Sponsor Name:Amgen Inc
    Full Title: A Randomized Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndr...
    Medical condition: Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS). ------------------------------------------------------------------------------ Síndrome Mielodisplásico (SMD) de Riesgo Bajo o Intermedio-1
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028533 Myelodysplastic syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) SK (Prematurely Ended) NL (Completed) CZ (Prematurely Ended) IE (Completed) AT (Prematurely Ended) DE (Completed) HU (Completed) BE (Completed) GB (Completed) DK (Completed) SE (Prematurely Ended) FR (Completed) IT (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-001516-24 Sponsor Protocol Number: 20060197 Start Date*: 2007-08-23
    Sponsor Name:Amgen Inc
    Full Title: An Open Label Extension Study Evaluating the Safety of Long Term Dosing of Romiplostim in Thrombocytopenic Subjects with Myelodysplastic Syndromes (MDS)
    Medical condition: Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028533 Myelodysplastic syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FR (Completed) SE (Prohibited by CA) BE (Completed) DE (Completed) ES (Completed) HU (Completed) PL (Completed) CZ (Completed) AT (Completed) SK (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001132-22 Sponsor Protocol Number: GEM-1202 Start Date*: 2014-02-24
    Sponsor Name:Grupo Español Multidisciplinar de Melanoma
    Full Title: A MULTICENTER, SINGLE ARM, PHASE 2 CLINICAL STUDY ON THE COMBINATION OF RADIATION THERAPY AND IPILIMUMAB, FOR THE TREATMENT OF PATIENTS WITH MELANOMA AND BRAIN METASTASES.
    Medical condition: Patients with melanoma and brain metastases
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005010-30 Sponsor Protocol Number: KTE-C19-104 Start Date*: 2017-09-27
    Sponsor Name:Kite Pharma, Inc.
    Full Title: A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-4)
    Medical condition: Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Ongoing) DE (Trial now transitioned) FR (Trial now transitioned) CZ (Trial now transitioned) SE (Completed) BE (Completed) PL (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA